Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in patients naive to, or progressed on, ipilimumab (IPI).
Jeffrey S. Weber(NYU Langone Health), Ann Chen(Moffitt Cancer Center), Jodi L. Kroeger(Moffitt Cancer Center), Geoffrey T. Gibney(Georgetown University), Donna Gallenstein(Moffitt Cancer Center), Pingyan Cheng(University of Tampa), Allison Richards(Moffitt Cancer Center), Alberto J. Martinez(Moffitt Cancer Center), Bin Yu(First Affiliated Hospital of Zhengzhou University), Xiuhua Zhao(Moffitt Cancer Center), Eric A. Welsh(Moffitt Cancer Center), Xiaotao Qu(The Affiliated Yongchuan Hospital of Chongqing Medical University), Ragini R. Kudchadkar
Cited by 14
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k